Health Condition 1: B20- Human immunodeficiency virus [HIV]disease
Conditions
Interventions
None listed
Sponsors
Fungal Infection Study Forum
Eligibility
Inclusion criteria
Inclusion criteria: • Adult HIV infected patients with age more than 18 years with first episode of CM • Diagnosis of CM arrived by CSF Cryptococcal Antigen (CrAg) Positive or Cryptococcal culture positive
Exclusion criteria
Exclusion criteria: 1. Patient receiving Antiretroviral treatment. 2. Pregnancy. 3. History of cryptococcal meningitis in the past, recurrence of CM 4. Patients with other co-infections (tuberculous meningitis, varicella zoster/herpes meningo-encephalitis, neurosyphilis, toxoplasmosis) 5. Not willing to participate or refuse consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of paradoxical reaction following anti fungal treatmentTimepoint: 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| • Determining clinical and laboratory features of PR in HIV CM • Compare changes in the various inflammatory markers in the CSF (local inflammation) and serum (Systemic inflammation) at baseline, day 7 and 14 after antifungal treatment in patients with and without PR and outcome. • CSF Opening pressure (OP), CSF CRP, CSF Lactate, White cells count, differential count, protein, glucose. • Any difference in PR after D-AmB therapy and L-AmB containing therapy. • Percentage of patients achieving sterile CSF culture after 1 and 2 weeks of antifungal therapy in HIV • To study cryptococcal species and its drug susceptibility in HIV associated CM • Species distributions and Drug susceptibility pattern and outcome at 8 and 12 weeks Timepoint: 12 weeks | — |
Countries
India
Contacts
Public ContactAtul Patel
Sterling Hospitals
Outcome results
None listed